Industry News

New Surgical Experience

VSY Biotechnology GmbH has launched Protectalon Duo. “Protectalon DUO Kit demonstrates VSY’s commitment to Ophthalmic Surgery Eye Care Professionals and will help to meet their OVD needs at different stages of cataract surgery with a single kit. It is available now for safe, fast and smooth surgery,” said a company spokesperson.

Protectalon DUO is a dual pack containing high filling volume of one unit cohesive (14mg/mL, 1.1mL) and one unit dispersive (30mg/ml, 1.1ml) NaHA-based OVDs, providing reliable anterior chamber maintenance with exceptional cohesivity and superior endothelial cell protection, according to VSY.

The product has CE and it is now available in Europe, said the spokesperson. “VSY Biotechnology GmbH is an innovation-driven company with its progressive R&D activities in ophthalmology, orthopaedics, aesthetics and biotechnologic drugs. VSY Biotechnology focuses on developing, designing and manufacturing superior, state-ofthe-art products to serve doctors, patients and consumers beyond their expectations,”

he said. www.vsybiotechnology.com

DENOISING SOFTWARE

NIDEK has announced the launch of the B-scan Denoising Software for the NIDEK OCT series.

“This software converts a B-scan retinal OCT image to a high-definition image by a denoising technique using deep learning,” said a NIDEK spokesperson. “A large data set of images that are each averaged from 120 images are used as teaching data for deep learning to create clear retinal images comparable to images generated by averaging 120 images,” he said. “Different from image averaging, which is an ordinal technique to create clear B-scan images, this unique denoising technique does not require capturing multi-frame images to remove speckle noise. This feature provides better patient flow and increased patient comfort. Providing exquisite image quality, this software is particularly useful when capturing multiple B-scans for wide area screening,” said the spokesperson. www.nidek-intl.com

MEDICAL DEVICES PARTNERSHIP

EVEON and Laboratoires Théa have announced a partnership that will assist both companies in the development of innovative medical devices.

“We are delighted to be able to join forces with EVEON. This partnership is part of our continued commitment in favour of innovative solutions for the care of eye disorders. Connected medical devices are a revolution that must be made available to eyecare professionals for the greater benefit of their patients,” said Jean-Frédéric Chibret, President of Laboratoires Théa.

“This joint endeavour with Théa Open Innovation is a pledge of confidence and commitment. We are proud to contribute together to the development of new-generation devices that respond to the challenges of modern medicine, which seeks to become more personalised, more responsive to each patient’s needs,” said Vincent Tempelaere, CEO of EVEON. www.eveon.eu, www.laboratoires-thea.com

NEWS IN BRIEF

GREEN LASER SYSTEM

Norlase has been granted the European CE Mark for the LION™ green laser system, which the company says combines the Keeler Vantage Plus diagnostic indirect with Norlase’s groundbreaking compact laser technology into one device.

“We are excited to greet 2021 with this important milestone,” said Oliver Hvidt, Norlase President and CEO. “With CE Mark approval for LION, following the recent establishment of our strategic distribution partnerships, we have expanded our reach and will arm even more ophthalmologists with innovative laser solutions to optimise practice efficiency and workflow,” said Mr Hvidt. www.norlase.com

GLAUCOMA GUIDELINES

IRIDEX has reported that MicroPulse Transscleral Laser Therapy (TLT), which is performed using the IRIDEX Cyclo G6® Laser System and MicroPulse P3® Delivery Device, has been included in the European Glaucoma Society (EGS) Terminology and Guidelines for Glaucoma. The EGS guidelines represent recommendations on the diagnosis and management of glaucoma to standardise practice within the European Union. The new guidelines, the Society’s 5th edition, were presented at the Annual EGS Meeting on 12-13 December 2020.

“We are very encouraged with the broadening recognition of MicroPulse TLT in the ophthalmic community,” said David Bruce, CEO, IRIDEX. www.iridex.com

MARKETING AUTHORISATION

Aerie Pharmaceuticals has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of the marketing authorisation application (MAA) for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%.

“We are delighted that the CHMP has adopted a positive opinion for Roclanda®,” said Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer at Aerie.

Roclanda is currently marketed as Rocklatan® in the United States and is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or hypertension. www.aeriepharma.com